Trial Profile
A Phase 2, 52 Week, Single Center, Open-Label Study Utilizing Imaging Techniques and Evaluating the Safety and Efficacy of SM04690 Injectable Suspension for the Treatment of Moderately to Severely Symptomatic Knee Osteoarthritis
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 14 May 2019
Price :
$35
*
At a glance
- Drugs Lorecivivint (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Samumed
- 20 Feb 2019 Status changed from not yet recruiting to recruiting.
- 24 Oct 2018 New trial record